Malaria: the past and the present
Malaria is a severe disease caused by parasites of the genus Plasmodium, which is
transmitted to humans by a bite of an infected female mosquito of the species Anopheles …
transmitted to humans by a bite of an infected female mosquito of the species Anopheles …
Malaria vaccines: recent advances and new horizons
The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
[图书][B] Lutte antivectorielle et élimination de la trypanosomiase humaine africaine (THA) à gambiense: réunion conjointe d'experts FAO/OMS (Réunion en ligne) 5–6 …
World Health Organization - 2022 - books.google.com
Page 1 PROGRAMME DE LUTTE CO CONTRE lutte contre LA de Programme SOMOSE
AFRICAINE PLTA FAO-AIEA - OMS - UA PROMOUVOIR L'AGRICULTURE ET LA SANTÉ la …
AFRICAINE PLTA FAO-AIEA - OMS - UA PROMOUVOIR L'AGRICULTURE ET LA SANTÉ la …
[HTML][HTML] Safety and efficacy of a monoclonal antibody against malaria in Mali
K Kayentao, A Ongoiba, AC Preston… - … England Journal of …, 2022 - Mass Medical Soc
Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …
Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria
RL Wu, AH Idris, NM Berkowitz, M Happe… - … England Journal of …, 2022 - Mass Medical Soc
Background New approaches for the prevention and elimination of malaria, a leading cause
of illness and death among infants and young children globally, are needed. Methods We …
of illness and death among infants and young children globally, are needed. Methods We …
A monoclonal antibody for malaria prevention
MR Gaudinski, NM Berkowitz, AH Idris… - … England Journal of …, 2021 - Mass Medical Soc
Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …
Malaria vaccines since 2000: progress, priorities, products
PE Duffy, J Patrick Gorres - npj Vaccines, 2020 - nature.com
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure
PD Kwong, JR Mascola - Immunity, 2018 - cell.com
HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …
Advances and opportunities in malaria population genomics
Almost 20 years have passed since the first reference genome assemblies were published
for Plasmodium falciparum, the deadliest malaria parasite, and Anopheles gambiae, the …
for Plasmodium falciparum, the deadliest malaria parasite, and Anopheles gambiae, the …
A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver
LT Wang, LS Pereira, Y Flores-Garcia, J O'Connor… - Immunity, 2020 - cell.com
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …